

***Dermatologic and Ophthalmic Drugs Advisory Committee
Meeting***

June 17-18, 2008

On June 17, 2008, the committee will discuss biologic licensing application (BLA) 125261, ustekinumab, a human monoclonal antibody, Centocor, Inc., proposed for the treatment of moderate to severe psoriasis. On June 18, 2008, the committee will discuss supplemental biologic licensing application (sBLA) 103795/5350, etanercept, a lyophilized powder for subcutaneous injection, Immunex Corporation, proposed for the treatment of moderate to severe psoriasis in the pediatric population.

Important Notice

**Dermatologic and Ophthalmic Drugs Advisory
Committee Meeting**

June 17-18, 2008

Change in Meeting Location

Update Meeting Location

The Hilton Washington DC/Silver Spring

8727 Colesville Road

Silver Spring, Maryland 20910

Hotel Phone:

301-589-5200 (local)

1-800-445-8667

Contact Person:

Yvette Waples, Pharm.D.

Center for Drug Evaluation and Research

5600 Fishers Lane

Rockville, Maryland 20857

Phone: 301-827-7001

Fax: 301-827-6776

Yvette.waples@fda.hhs.gov

No other changes made to this meeting.